Dr. Reddys Laboratories is currently trading at Rs. 4441.00, up by 3.05 points or 0.07% from its previous closing of Rs. 4437.95 on the BSE.
The scrip opened at Rs. 4460.00 and has touched a high and low of Rs. 4466.55 and Rs. 4421.00 respectively. So far 3988 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 4754.30 on 10-Aug-2020 and a 52 week low of Rs. 2495.40 on 29-Aug-2019.
Last one week high and low of the scrip stood at Rs. 4520.95 and Rs. 4401.00 respectively. The current market cap of the company is Rs. 73783.14 crore.
The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.97% and 15.25% respectively.
Dr. Reddy’s Laboratories has launched Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health. The company’s Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
